ITJ

With a Two-Year Revenue Growth of 3,831%, ITJ Ranks No. 5 on Inc. Magazine's List of the Pacific Region's Fastest-Growing Private Companies

Retrieved on: 
Donnerstag, März 2, 2023
Growth, Regionals, SAN, Name, ITJ, Airline, Pacific Ocean

SAN DIEGO, March 2, 2023 /PRNewswire-PRWeb/ -- Inc. Magazine today revealed that ITJ is No. 5 on its third annual Inc. 5000 Regionals: Pacific list, the most prestigious ranking of the fastest-growing Pacific private companies, based in Alaska, Hawaii, California, Oregon, and Washington. Born of the annual Inc. 5000 franchise, this regional list represents a unique look at the most successful private companies within the Pacific economy generating sustainable growth and jobs.

Key Points: 
  • 5 on its third annual Inc. 5000 Regionals: Pacific list, the most prestigious ranking of the fastest-growing Pacific private companies, based in Alaska, Hawaii, California, Oregon, and Washington.
  • Born of the annual Inc. 5000 franchise, this regional list represents a unique look at the most successful private companies within the Pacific economy generating sustainable growth and jobs.
  • "We are honored to be named one of the Pacific Region's fastest-growing private companies.
  • The companies on this list show a remarkable rate of growth across all industries in the Pacific.

Aclaris Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Dienstag, November 8, 2022
Janus, MK2, GLOBE, Rheumatoid arthritis, Private Securities Litigation Reform Act, IND, Lilly, Ulcerative colitis, Risk, Atopic dermatitis, Headache, Patent, PK, Eli Lilly and Company, Food, Psoriatic arthritis, Hidradenitis suppurativa, JAK3, G&A, COVID-19, HS, Therapy, Methotrexate, Annual report, MAD, R, NASDAQ, SAD, Alopecia areata, Safety, U.S. Securities and Exchange Commission, Pharmacokinetics, Biomarker, Program, JAK, ITJ, Female, AD, Absorption, Research, Patient, ACRS, Male, ITK, RA, FDA, PD, Pharmaceutical industry, Copper, Risk management, Publishing, Hydraulic machinery, Reinsurance

WAYNE, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2022 and provided a corporate update.

Key Points: 
  • If allowed, Aclaris intends to initiate a Phase 1 MAD trial of ATI-2138 in healthy subjects by the end of 2022.
  • Net loss was $20.0 million for the third quarter of 2022 compared to $21.1 million for the third quarter of 2021.
  • Total revenue was $19.0 million for the third quarter of 2022 compared to $1.7 million for the third quarter of 2021.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

A new Technology Center of Excellence opens Tijuana, Mexico

Retrieved on: 
Donnerstag, August 4, 2022
Consulate, Internet, CEO, Growth, Technology Center, Creativity, Government, Innovation, List of life sciences, 2007 Baja California state election, Symbiosis, ITJ, Economic development, World, Time, Efficiency, Video game

TIJUANA, Mexico,  Aug. 4, 2022 /PRNewswire-PRWeb/ -- For this milestone, the company gathered representatives of government and binational leaders. Mexico's Consulate in San Diego, the U.S. Consulate General in Tijuana, and Baja California State's Secretariat of Economic Development and Innovation were among the guests. In addition, the World Trade Center San Diego, Tijuana EDC, San Diego EDC, U.S., and companies leading software development and biotech innovation in the region also attended the event.

Key Points: 
  • ITJ opened its new Technology Center of Excellence in Tijuana, Mexico.
  • TIJUANA, Mexico, Aug. 4, 2022 /PRNewswire-PRWeb/ -- For this milestone, the company gathered representatives of government and binational leaders.
  • To enable companies to become more competitive in mind, the new center integrates spaces for collaborative environments, scrum rooms, and more.
  • With a unique BOT (build, operate, and transfer) model that sources only the best digital talent available, ITJ enables companies in the U.S. to create technology centers of excellence in Mexico.

Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Mittwoch, August 3, 2022
Janus, HS, NASDAQ, Psoriasis, U.S. Securities and Exchange Commission, RA, Safety, Annual report, Risk, Doctor of Philosophy, Â, Atopic dermatitis, MK2, R, Private Securities Litigation Reform Act, Hidradenitis suppurativa, Psoriatic arthritis, Patient, Methotrexate, ACRS, ITJ, IND, MAD, Rheumatoid arthritis, AD, GLOBE, Sale, G&A, JAK, Pharmacokinetics, ATM, COVID-19, Research, Therapy, SAD, Pharmaceutical industry, Cryptocurrency, Video game, Vaccine, Hydraulic machinery, Reinsurance, Online gambling, MD

WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2022 and provided a corporate update.

Key Points: 
  • WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2022 and provided a corporate update.
  • During the second quarter we also were able to raise additional capital, which extended our expected cash runway to the end of 2025.
  • Net loss was $20.5 million for the second quarter of 2022 compared to $18.2 million for the second quarter of 2021.
  • Total revenue was $1.5 million for the second quarter of 2022 compared to $1.8 million for the second quarter of 2021.

Girls Inc. of San Diego Recognizes Maritza Diaz, Kim Folsom and Janessa Goldbeck at SHE LEADS: Strong, Smart and Bold Women of San Diego event

Retrieved on: 
Montag, August 1, 2022
Founder, Female, Woman, CEO, SAN, Government, CBS, Vet, Girls, Inc., Farmer, SHE, ITJ, Leadership, Policy, PDT, CBS 8, Marines, Life, Computer science and engineering, Toy, Engineering, Technology, Science, Mathematics

SAN DIEGO, Aug. 1, 2022 /PRNewswire/ -- On Wednesday, September 28, Girls Inc. of San Diego will host its second annual SHE LEADS: Strong, Smart and Bold Women of San Diego event.

Key Points: 
  • SAN DIEGO, Aug. 1, 2022 /PRNewswire/ -- On Wednesday, September 28, Girls Inc. of San Diego will host its second annual SHE LEADS: Strong, Smart and Bold Women of San Diego event.
  • "Protecting and advancing women's rights has never been more critical," said Sandra Ainslie, CEO of Girls Inc. of San Diego.
  • The outdoor event will take place on September 28 from 6-8 pm PDT at the Farmer & The Seahorse in San Diego.
  • For more than 50 years, the nonprofit organization has supported high-need girls with no-cost programming to help them succeed in life.

Aclaris Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Retrieved on: 
Dienstag, Mai 10, 2022
Janus, MK2, Central nervous system, COVID-19, Neurodegeneration, Drug development, AD, Private Securities Litigation Reform Act, Eli Lilly and Company, Microglia, IND, U.S. Securities and Exchange Commission, NASDAQ, Pharmacokinetics, GLOBE, CNS, Company, Safety, Research, Janssen Pharmaceuticals, Translation, Hidradenitis suppurativa, Patient, Atopic dermatitis, Survival, Horizon Therapeutics, Cambridge Antibody Technology, Inflammatory bowel disease, Psoriatic arthritis, Risk, Annual report, MedImmune, R, Methotrexate, Drug, RA, Sale, ACRS, JAK, Psoriasis, Therapy, G&A, HS, SAD, Rheumatoid arthritis, Technology, CEO, Horizon, ATM, ITJ, Pharmaceutical industry, Food delivery, Video game

WAYNE, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2022 and provided a corporate update.

Key Points: 
  • WAYNE, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2022 and provided a corporate update.
  • Additionally, in April 2022, Aclaris sold approximately 4.8 million shares under its ATM facility for aggregate net proceeds of $73 million.
  • Net loss was $18.8 million for the first quarter of 2022 compared to $28.8 million for the first quarter of 2021.
  • Total revenue was $1.5 million for the first quarter of 2022 compared to $1.8 million for the first quarter of 2021.

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Retrieved on: 
Donnerstag, Februar 24, 2022
Janus, GLOBE, U.S. Securities and Exchange Commission, HS, Compliance, Population, SAD, Retirement, Risk, Pharmacokinetics, JAK, NASDAQ, Atopic dermatitis, Psoriasis, Neurodegeneration, Annual report, Research, COVID-19, Therapy, Inflammatory bowel disease, Private Securities Litigation Reform Act, Safety, ITJ, G&A, RA, MK2, Methotrexate, Central nervous system, Acquisition, ACRS, IND, Rheumatoid arthritis, Leadership, AD, Cancer, R, Patient, Survival, CEO, CNS, Confluence, Microglia, Pharmaceutical industry, Management, Bank, Animal, Video game, Lithium

WAYNE, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2021 and provided a corporate update.

Key Points: 
  • WAYNE, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2021 and provided a corporate update.
  • Aclaris anticipates increasing the size of the patient population from approximately 195 to approximately 240 subjects and expects topline data in 2023.
  • Net loss was $22.8 million for the fourth quarter of 2021 compared to $13.2 million for the fourth quarter of 2020.
  • Total revenue was $1.5 million for the fourth quarter of 2021 compared to $1.6 million for the fourth quarter of 2020.

Aclaris Therapeutics Provides R&D Update

Retrieved on: 
Dienstag, Januar 11, 2022
U.S. Securities and Exchange Commission, Research, Patient, R, ACR20, Private Securities Litigation Reform Act, Methotrexate, D, COVID-19, Inflammatory bowel disease, Abscess, Safety, Risk, NASDAQ, IL6, CEO, GLOBE, ACRS, Leadership, ITJ, Lymphocyte, Psoriasis, MK2, Therapy, Pharmacokinetics, Pharmacology, RA, Company, HS, American College of Rheumatology, Chemokine, American College, Rheumatoid arthritis, Degenerative disease, IL8, Annual report, Pharmaceutical industry

WAYNE, Pa., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today provides an update on the status of certain of its clinical programs and on its research and development (R&D) operations.

Key Points: 
  • WAYNE, Pa., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today provides an update on the status of certain of its clinical programs and on its research and development (R&D) operations.
  • Aclaris has bolstered its R&D group, including in the areas of clinical, preclinical and discovery, quality, pharmacology, and regulatory.
  • Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options.
  • These documents are available under the SEC Filings page of the Investors section of Aclaris website at www.aclaristx.com.

Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021

Retrieved on: 
Donnerstag, November 18, 2021
Patient, Private Securities Litigation Reform Act, Regulation of tobacco by the U.S. Food and Drug Administration, CEO, Psoriasis, Risk, ACRS, Annual report, IND, COVID-19, ITJ, U.S. Securities and Exchange Commission, GLOBE, Webcast, Therapy, NASDAQ, Food, Fine chemical, Pharmaceutical industry

WAYNE, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it will host a virtual R&D Day on Tuesday, December 7, 2021 from 10:00 a.m. to 12:00 p.m. ET.

Key Points: 
  • WAYNE, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it will host a virtual R&D Day on Tuesday, December 7, 2021 from 10:00 a.m. to 12:00 p.m.
  • We look forward to providing more details about this clinical program and our other pipeline assets at our upcoming virtual R&D Day in early December.
  • The virtual R&D Day, intended for investors and analysts, will include the following topics:
    Management will host the event via conference call and webcast, with an accompanying slide presentation.
  • A webcast of the event may be accessed through the Events page of the Investors section of Aclaris website, www.aclaristx.com.

Aclaris Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update

Retrieved on: 
Dienstag, November 2, 2021
Janus, Pancreatic cancer, Breast cancer, Quality, Compliance, Research, Accounting, Entrepreneurship, ITJ, MK2, Retirement, Survival, New Drug Application, Patient, Private Securities Litigation Reform Act, NASDAQ, Psoriasis, Corporation, Microglia, U.S. Securities and Exchange Commission, Human resources, ACRS, Atopic dermatitis, Annual report, Risk, Confluence, CEO, Board, Neurodegeneration, COVID-19, Corporate communication, JAK, Inflammatory bowel disease, Hidradenitis suppurativa, IND, R, G&A, Therapy, Rheumatoid arthritis, Acquisition, Bone loss, GLOBE, Board of directors, Pharmaceutical industry, Medical imaging, Bank, Animal, Financial adviser, Reinsurance, Fine chemical

WAYNE, Pa., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2021 and provided a corporate update.

Key Points: 
  • WAYNE, Pa., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2021 and provided a corporate update.
  • Aclaris plans to progress zunsemetinib into a Phase 2b trial in moderate to severe rheumatoid arthritis in the fourth quarter of 2021.
  • Net loss was $21.1 million for the third quarter of 2021 compared to $10.7 million for the third quarter of 2020.
  • Total revenue was $1.7 million for the third quarter of 2021 compared to $1.4 million for the third quarter of 2020.